Home        Sitemap        Contact us 
 
News and Scientific Events
 

06/28/2017

Salt Lake City: June 28, 2017, 9.00 AM EST: Arrien Pharmaceuticals announces a worldwide license agreement for ARN-6039, a clinical stage oral ROR-γt inverse agonist for the treatment of psoriasis and potentially other autoimmune disorders.
http://www.businesswire.com/news/home/20170628005166/en/Arrien-Pharmaceuticals-Announces-Worldwide-License-Agreement-ARN-6039

01/11/2017

Salt Lake City: January 11, 2017
Arrien Pharmaceuticals Management to participate in 2017 AAD (American Academy of Dermatology) Annual Meeting on March 03-07, 2017 in Orlando, Florida.
https://www.aad.org/meetings/annual-meeting

01/11/2017

Salt Lake City: January 11, 2017
Arrien Pharmaceuticals Management to participates in AACR Annual Meeting to be held on April 1-5, 2017 in Washington, D.C.
http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=105&utm_source=aacr-org&utm_campaign=am17&utm_medium=mouseover#.WHSyGfkrJnI

01/09/2017

Salt Lake City: January 09, 2017
Arrien Pharmaceuticals management participates in the J.P. Morgan 35th Annual Healthcare Conference on 9 - 12 January 2017 in San Francisco, CA, USA.

01/08/2017

Salt Lake City: January 08, 2017
Arrien Pharmaceuticals Management participated in “The 4th Annual Dermatology Summit” was held in San Francisco, California on January 08, 2017.
http://www.dermsummit.com/2017

10/03/2016

Salt Lake City: October 03, 2016: Arrien Pharmaceuticals management participates Bio INVESTOR Forum at San Francisco, California on October 18-9 2016.
https://www.bio.org/events/bio-investor-forum

08/01/2016

Salt Lake City: Aug 1, 2016: Arrien Pharmaceuticals pleased to announce that the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Selection Committee has accepted the abstract titled "Development of ARN-6039, an RORyt/IL-17-TH17 specific agent for treatment of multiple sclerosis and evaluation of phase 1 trials in normal controls" for a presentation at the Annual Meeting to be held in London, England on 14-17 September 2016.

Session Title: Poster Session 2
Session Date: Friday, 16 September 2016
Session Time: 15:30-17:00

06/01/2016

Arrien Pharmaceuticals Management to participate and present the company’s pipeline overview at BIO International Convention on June 6-9, 2016 | Moscone Center, San Francisco, CA.
http://convention.bio.org/2016

05/23/2016

Arrien Pharmaceuticals management to participate 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

05/16/2016

Arrien Pharmaceuticals initiated the First in Human (FIH) Phase I Clinical trials for Safety, Tolerability, and Pharmacokinetic Profile of ARN-6039 in health subjects on May16, 2016.

05/09/2016

Arrien Pharmaceuticals to initiate the Phase I Clinical trials for Safety, Tolerability, and Pharmacokinetic Profile of ARN-6039 in health subjects in May 2016.

04/29/2016

Arrien Pharmaceuticals successfully completed ARN-6039 IND enabling studies demonstrating significant efficacy and disease control in disease models of Multiple Sclerosis (MS).
In April 2016, the U.S. Food and Drug Administration accepted our Investigational New Drug application to begin a Phase 1 clinical trial on ARN-6039 for Safety, Tolerability, and Pharmacokinetic Profile. ARN-6039 an agent for the treatment of MS and we are in the process of initiating clinical trials on May 2016.

04/18/2016

Arrien Pharmaceuticals management participated and presented pre-clinical data on ROR/IL-17 program at the 68th AAN (American Academy of Neurology) Annual Meeting on April 15-21, 2016, at the Vancouver Convention Centre in Vancouver, BC, Canada.
https://www.aan.com/conferences/2016-annual-meeting

11/05/2015

Arrien Pharmaceutical Management participated in “Annual BioUtah Life Sciences Summit Meeting” was held on November 5, 2015 at Hilton Hotel in Salt Lake City, UT, USA.
http://www.bioutah.org

05/07/2015

Arrien Pharmaceuticals management participated and presented at the 10th Protein Kinases in Drug Discovery Conference, which will take place on May 7-8, 2015 in Berlin, Germany.

04/18/2015

Arrien Pharmaceuticals management participated at the 67th AAN (American Academy of Neurology) Annual Meeting on April 18-25, 2015, at the Walter E. Washington Convention Center in Washington, DC.

09/09/2014

Arrien Pharmaceuticals today announced that the U.S. Patent and Trademark Office has issued U.S. Patents No. 8,791,112 B2; July 29, 2014.

 
The term of the patent is 20 years from the earliest effective filing data March 2012, claim pharmaceutical compositions matter comprising of pre-clinical stage ORS-1104 and related compounds useful as protein kinase inhibitors, specifically LRRK2 (Leucine-Rich Repeat Kinase-2) for the treatment of Parkinson's Disease, Alzheimer's Disease, Down's Syndrome, Huntington's Disease, other Neurodegenerative and Central Nervous System disorders.
 
09/01/2014
Arrien Pharmaceuticals pleased to announce that the American College of Rheumatology (ACR) Selection Committee has accepted the abstract titled "Discovery of ARN-4079 - a Potent, Orally Available Dual Target Inhibitor of Janus Kinase 3 (JAK3) and Interleukin-2 Inducible T-Cell Kinase (ITK) for Rheumatoid Arthritis" for a presentation at the 2014 ACR/ARHP Annual Meeting, to be held in Boston, MA on November 14-19, 2014.
 
The schedule for our presentation is as follows: 
Session Type/Number: Poster/1459
 
Session Name: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Novel therapies, Biosimilars, Strategies and Mechanisms in Rheumatoid Arthritis 
 
Presentation Time: Monday, November 17, 2014 at 9:00-11:00 AM
 
Location: Boston Convention and Exhibit Center - Exhibit Hall B 
07/10/2014

Arrien Pharmaceuticals Management will be participating in American College of Rheumatology (ACR) 2014 Annual Meeting schedule to be held on November 14-19, 2014 in Boston, Massachusetts.

06/27/2014

Arrien Pharmaceuticals Management participated in The USA-India Chamber of Commerce 2014 meeting on “US-India BioPharma & Healthcare Summit” was held on Friday June 27th, 2014 at the Marriott Cambridge, Massachusetts, 02142, USA.

04/05/2014

Arrien Pharmaceuticals Scientific team first-time presents preclinical data showing ARN-3236 inhibits clinically relevant target SIK2 at AACR 2014.

Salt Lake City, UT., April 3, 2013 - Arrien Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the acceptance of an abstract covering internally funded SIK2 inhibitor data for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2014, April 5-9 In San Diego, CA.
 
Title: Highly potent and orally available SIK2 inhibitors block growth of human ovarian cancer cells in culture and xenografts
Abstract Number: 749
Session ID: Experimental and Molecular Therapeutics 3
Session Date and Time: Sunday Apr 6, 2014 1:00 PM - 5:00 PM
Location: Hall A-E, Poster Section 31
Read More..
03/29/2014

Arrien Pharmaceuticals Management participated in The EPPIC 2014 Annual Conference “Interdisciplinary Innovations in Life Sciences” was held on Saturday, March 29th, 2014 at the Westin SFO Airport, 1 Old Bayshore Highway, Millbrae, CA, 94030, USA.

11/06/2013

Arrien Pharmaceuticals Management participated in entrepreneurial track speaker session of “Annual BioUtah Summit Conference” was held on November 6, 2013 at the Grand America Hotel in Salt Lake City, UT, USA.

09/19/2013

Arrien Pharmaceuticals Management participating “Rocky Mountain Life Science Investor & Partnering Conference” on September 18-19, 2013 at Ritz-Carlton, Denver, CO, USA.

04/22/2013

Arrien Pharmaceuticals Management participated and presented the company\'s business and scientific overview at BIO International Convention on April 22-25th at McCormick Place Chicago, Illinois, USA.

03/20/2013

Arrien Pharmaceuticals Management participated and presented the company's business and scientific overview at The Life Sciences and Healthcare Venture Summit, hosted by youngStartup Ventures, on March 20th at Digital Sandbox, New York City, USA.

11/06/2012

Arrien Pharmaceuticals and Laboratory of Cell Signaling and Metabolic Disease, National Institute of Biomedical Innovation (NIBIO) Osaka, Japan headed by Dr. Hiroshi Takemori, PhD have signed a sponsored research collaboration agreement to study the role of SIK2 and SIK3 protein targets; its clinical relevance, association in Cancer, Diabetes diseases and inhibition by target specific SIK2 and SIK3 inhibitors.

08/16/2012

The lead back-up candidate ORS-1104 is now advanced into IND enabling stage of development for Parkinson's disease.

05/05/2012

ORS-1006 originally nominated candidate; an extensive pre-clinical toxicology and pharmacology studies were conducted for Parkinson’s disease indication to be progressed latter this year. Currently the back-up candidate compound ORS-1104 entered into pre-clinical development has been shown to be highly potent, selective and is effective in mouse models of PD.

05/05/2012

Arrien Pharmaceuticals Management and Scientific Advisory members participating and presenting at Next-Gen Kinase Inhibitors Conference taking place in June 4-6, 2012 at Boston, Cambridge, MA.

12/14/2011

Arrien Pharmaceuticals Management participating and presenting at Molecular Med TRI-CON - Partnering Forum, taking place February 19 - 20, 2012 in San Francisco, CA.

10/24/2011

Dr. Philip LoGrasso appointed to the Scientific Advisory Board for CNS/Neurodegenerative Diseases.
Read More..

10/03/2011

Arrien Pharmaceuticals and MD Anderson Cancer Center of The University of Texas have signed a sponsored research collaboration agreement to conduct the cellular and in vivo efficacy of SIK2 inhibitors discovery by Arrien Pharmaceuticals scientists for treating Ovarian Cancer.  Robert C. Bast, Jr., M.D, Vice President for Translational Research and his team discovered new Ser/Thr kinase target SIK2 and the study was published in Cancer Cell, 2010, 18(2), 109-121. Their published key findings on Salt Inducible Kinase 2 (SIK2) suggests that the overexpressed/increased SIK2 levels in approximately 30% of ovarian cancers and were associated with poorer survival in women with the disease. Inhibition of SIK2 with inhibitors is effective in treating Ovarian Cancer and halt the cancer growth.

09/12/2011

Arrien Pharmaceuticals Founder\'s closes $2.0 Million Series A Financing. Read More..

09/06/2011

Arrien Pharmaceuticals Management participating in 4th CNS Partnering and Deal-making • Sep 22-23, 2011 • San Francisco, CA, USA

07/01/2011

Arrien Pharmaceuticals secures initial funding from company founders and initiated its New Drug Discovery (NDD), Medicinal Chemistry and Screening research activities on several of its pipeline programs.

07/01/2011

Arrien Pharmaceuticals, a small molecule Drug Discovery Company entered into an agreement with Oros Pharmaceuticals Pvt. Ltd (India) a  Neurodegenerative/CNS Drug Discovery Company to combine the discovery efforts to advance the Oros Pipeline.

07/01/2011

Arrien Pharmaceuticals, a small molecule Drug Discovery Company based in USA entered into an agreement with Alveus Pharmaceuticals Pvt. Ltd (India) for all of its early Medicinal Chemistry/Discovery Research Services.
Alveus Pharmaceuticals, a Contract Research Organization (CRO) offers custom synthesis services for the Pharmaceutical/Biotechnology industries, research institutes and Universities for their drug discovery research and development process.

06/06/2011

Arrien Pharmaceuticals Management participated in World Pharma Congress (WPC) Drug Discovery Summit meeting held on June 7-9, 2011 at Philadelphia on Targeting Alzheimer\'s and Parkinson\'s disease.

     
01/11/2017

Salt Lake City: January 11, 2017
Arrien Pharmaceuticals Management to participate in 2017 AAD (American Academy of Dermatology) Annual Meeting on March 03-07, 2017 in Orlando, Florida.
https://www.aad.org/meetings/annual-meeting

     
01/11/2017

Salt Lake City: January 11, 2017
Arrien Pharmaceuticals Management to participates in AACR Annual Meeting to be held on April 1-5, 2017 in Washington, D.C.
http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=105&utm_source=aacr-org&utm_campaign=am17&utm_medium=mouseover#.WHSyGfkrJnI

     
01/09/2017

Salt Lake City: January 09, 2017
Arrien Pharmaceuticals management participates in the J.P. Morgan 35th Annual Healthcare Conference on 9 - 12 January 2017 in San Francisco, CA, USA.

     
01/08/2017

Salt Lake City: January 08, 2017
Arrien Pharmaceuticals Management participated in “The 4th Annual Dermatology Summit” was held in San Francisco, California on January 08, 2017.
http://www.dermsummit.com/2017

     
10/03/2016

Salt Lake City: October 03, 2016: Arrien Pharmaceuticals management participates Bio INVESTOR Forum at San Francisco, California on October 18-9 2016.
https://www.bio.org/events/bio-investor-forum

     
08/01/2016

Salt Lake City: Aug 1, 2016: Arrien Pharmaceuticals pleased to announce that the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Selection Committee has accepted the abstract titled "Development of ARN-6039, an RORyt/IL-17-TH17 specific agent for treatment of multiple sclerosis and evaluation of phase 1 trials in normal controls" for a presentation at the Annual Meeting to be held in London, England on 14-17 September 2016.

Session Title: Poster Session 2
Session Date: Friday, 16 September 2016
Session Time: 15:30-17:00

     
06/01/2016

Arrien Pharmaceuticals Management to participate and present the company’s pipeline overview at BIO International Convention on June 6-9, 2016 | Moscone Center, San Francisco, CA.
http://convention.bio.org/2016

     
05/23/2016

Arrien Pharmaceuticals management to participate 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

     
05/16/2016

Arrien Pharmaceuticals initiated the First in Human (FIH) Phase I Clinical trials for Safety, Tolerability, and Pharmacokinetic Profile of ARN-6039 in health subjects on May16, 2016.

     
05/09/2016

Arrien Pharmaceuticals to initiate the Phase I Clinical trials for Safety, Tolerability, and Pharmacokinetic Profile of ARN-6039 in health subjects in May 2016.

     
04/29/2016

Arrien Pharmaceuticals successfully completed ARN-6039 IND enabling studies demonstrating significant efficacy and disease control in disease models of Multiple Sclerosis (MS).
In April 2016, the U.S. Food and Drug Administration accepted our Investigational New Drug application to begin a Phase 1 clinical trial on ARN-6039 for Safety, Tolerability, and Pharmacokinetic Profile. ARN-6039 an agent for the treatment of MS and we are in the process of initiating clinical trials on May 2016.

     
04/18/2016

Arrien Pharmaceuticals management participated and presented pre-clinical data on ROR/IL-17 program at the 68th AAN (American Academy of Neurology) Annual Meeting on April 15-21, 2016, at the Vancouver Convention Centre in Vancouver, BC, Canada.
https://www.aan.com/conferences/2016-annual-meeting

     
11/05/2015

Arrien Pharmaceutical Management participated in “Annual BioUtah Life Sciences Summit Meeting” was held on November 5, 2015 at Hilton Hotel in Salt Lake City, UT, USA.
http://www.bioutah.org

     
05/07/2015

Arrien Pharmaceuticals management participated and presented at the 10th Protein Kinases in Drug Discovery Conference, which will take place on May 7-8, 2015 in Berlin, Germany.

     
04/18/2015

Arrien Pharmaceuticals management participated at the 67th AAN (American Academy of Neurology) Annual Meeting on April 18-25, 2015, at the Walter E. Washington Convention Center in Washington, DC.

     
09/09/2014

Arrien Pharmaceuticals today announced that the U.S. Patent and Trademark Office has issued U.S. Patents No. 8,791,112 B2; July 29, 2014.

 
The term of the patent is 20 years from the earliest effective filing data March 2012, claim pharmaceutical compositions matter comprising of pre-clinical stage ORS-1104 and related compounds useful as protein kinase inhibitors, specifically LRRK2 (Leucine-Rich Repeat Kinase-2) for the treatment of Parkinson's Disease, Alzheimer's Disease, Down's Syndrome, Huntington's Disease, other Neurodegenerative and Central Nervous System disorders.
 
     
09/01/2014
Arrien Pharmaceuticals pleased to announce that the American College of Rheumatology (ACR) Selection Committee has accepted the abstract titled "Discovery of ARN-4079 - a Potent, Orally Available Dual Target Inhibitor of Janus Kinase 3 (JAK3) and Interleukin-2 Inducible T-Cell Kinase (ITK) for Rheumatoid Arthritis" for a presentation at the 2014 ACR/ARHP Annual Meeting, to be held in Boston, MA on November 14-19, 2014.
 
The schedule for our presentation is as follows: 
Session Type/Number: Poster/1459
 
Session Name: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Novel therapies, Biosimilars, Strategies and Mechanisms in Rheumatoid Arthritis 
 
Presentation Time: Monday, November 17, 2014 at 9:00-11:00 AM
 
Location: Boston Convention and Exhibit Center - Exhibit Hall B 
     
07/10/2014

Arrien Pharmaceuticals Management will be participating in American College of Rheumatology (ACR) 2014 Annual Meeting schedule to be held on November 14-19, 2014 in Boston, Massachusetts.

     
06/27/2014

Arrien Pharmaceuticals Management participated in The USA-India Chamber of Commerce 2014 meeting on “US-India BioPharma & Healthcare Summit” was held on Friday June 27th, 2014 at the Marriott Cambridge, Massachusetts, 02142, USA.

     
04/05/2014

Arrien Pharmaceuticals Scientific team first-time presents preclinical data showing ARN-3236 inhibits clinically relevant target SIK2 at AACR 2014.

Salt Lake City, UT., April 3, 2013 - Arrien Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the acceptance of an abstract covering internally funded SIK2 inhibitor data for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2014, April 5-9 In San Diego, CA.
 
Title: Highly potent and orally available SIK2 inhibitors block growth of human ovarian cancer cells in culture and xenografts
Abstract Number: 749
Session ID: Experimental and Molecular Therapeutics 3
Session Date and Time: Sunday Apr 6, 2014 1:00 PM - 5:00 PM
Location: Hall A-E, Poster Section 31
Read More..
     
03/29/2014

Arrien Pharmaceuticals Management participated in The EPPIC 2014 Annual Conference “Interdisciplinary Innovations in Life Sciences” was held on Saturday, March 29th, 2014 at the Westin SFO Airport, 1 Old Bayshore Highway, Millbrae, CA, 94030, USA.

     
11/06/2013

Arrien Pharmaceuticals Management participated in entrepreneurial track speaker session of “Annual BioUtah Summit Conference” was held on November 6, 2013 at the Grand America Hotel in Salt Lake City, UT, USA.

     
09/19/2013

Arrien Pharmaceuticals Management participating “Rocky Mountain Life Science Investor & Partnering Conference” on September 18-19, 2013 at Ritz-Carlton, Denver, CO, USA.

     
04/22/2013

Arrien Pharmaceuticals Management participated and presented the company\'s business and scientific overview at BIO International Convention on April 22-25th at McCormick Place Chicago, Illinois, USA.

     
03/20/2013

Arrien Pharmaceuticals Management participated and presented the company's business and scientific overview at The Life Sciences and Healthcare Venture Summit, hosted by youngStartup Ventures, on March 20th at Digital Sandbox, New York City, USA.

     
11/06/2012

Arrien Pharmaceuticals and Laboratory of Cell Signaling and Metabolic Disease, National Institute of Biomedical Innovation (NIBIO) Osaka, Japan headed by Dr. Hiroshi Takemori, PhD have signed a sponsored research collaboration agreement to study the role of SIK2 and SIK3 protein targets; its clinical relevance, association in Cancer, Diabetes diseases and inhibition by target specific SIK2 and SIK3 inhibitors.

     
08/16/2012

The lead back-up candidate ORS-1104 is now advanced into IND enabling stage of development for Parkinson's disease.

     
05/05/2012

ORS-1006 originally nominated candidate; an extensive pre-clinical toxicology and pharmacology studies were conducted for Parkinson’s disease indication to be progressed latter this year. Currently the back-up candidate compound ORS-1104 entered into pre-clinical development has been shown to be highly potent, selective and is effective in mouse models of PD.

     
05/05/2012

Arrien Pharmaceuticals Management and Scientific Advisory members participating and presenting at Next-Gen Kinase Inhibitors Conference taking place in June 4-6, 2012 at Boston, Cambridge, MA.

     
12/14/2011

Arrien Pharmaceuticals Management participating and presenting at Molecular Med TRI-CON - Partnering Forum, taking place February 19 - 20, 2012 in San Francisco, CA.

     
10/24/2011

Dr. Philip LoGrasso appointed to the Scientific Advisory Board for CNS/Neurodegenerative Diseases.
Read More..

     
10/03/2011

Arrien Pharmaceuticals and MD Anderson Cancer Center of The University of Texas have signed a sponsored research collaboration agreement to conduct the cellular and in vivo efficacy of SIK2 inhibitors discovery by Arrien Pharmaceuticals scientists for treating Ovarian Cancer.  Robert C. Bast, Jr., M.D, Vice President for Translational Research and his team discovered new Ser/Thr kinase target SIK2 and the study was published in Cancer Cell, 2010, 18(2), 109-121. Their published key findings on Salt Inducible Kinase 2 (SIK2) suggests that the overexpressed/increased SIK2 levels in approximately 30% of ovarian cancers and were associated with poorer survival in women with the disease. Inhibition of SIK2 with inhibitors is effective in treating Ovarian Cancer and halt the cancer growth.

     
09/12/2011

Arrien Pharmaceuticals Founder\'s closes $2.0 Million Series A Financing. Read More..

     
09/06/2011

Arrien Pharmaceuticals Management participating in 4th CNS Partnering and Deal-making • Sep 22-23, 2011 • San Francisco, CA, USA

     
07/01/2011

Arrien Pharmaceuticals secures initial funding from company founders and initiated its New Drug Discovery (NDD), Medicinal Chemistry and Screening research activities on several of its pipeline programs.

     
07/01/2011

Arrien Pharmaceuticals, a small molecule Drug Discovery Company entered into an agreement with Oros Pharmaceuticals Pvt. Ltd (India) a  Neurodegenerative/CNS Drug Discovery Company to combine the discovery efforts to advance the Oros Pipeline.

    
07/01/2011

Arrien Pharmaceuticals, a small molecule Drug Discovery Company based in USA entered into an agreement with Alveus Pharmaceuticals Pvt. Ltd (India) for all of its early Medicinal Chemistry/Discovery Research Services.
Alveus Pharmaceuticals, a Contract Research Organization (CRO) offers custom synthesis services for the Pharmaceutical/Biotechnology industries, research institutes and Universities for their drug discovery research and development process.

    
06/06/2011

Arrien Pharmaceuticals Management participated in World Pharma Congress (WPC) Drug Discovery Summit meeting held on June 7-9, 2011 at Philadelphia on Targeting Alzheimer\'s and Parkinson\'s disease.

     
-->
 
Copyright 2011, Arrien Pharmaceuticals, LLC. All rights reserved.